Gene Therapy News
-
Microneedle Market Projected to Reach $1.3 Billion by 2028, Reveals Latest BCC Research Study
Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. Ongoing research and numerous products in development make this market dynamic for newcomers entering the field. “According to the latest BCC Research study, ...
By BCC Research
-
Optimizing Monoclonal Antibody Production: Temperature And Osmolality’s Impact, Upcoming Webinar Hosted By Xtalks
In this free webinar sponsored by Advanced Instruments, gain insights into advances in monoclonal antibody production technology and manufacturing strategies. Attendees will learn why temperature and osmolality in cell culture are critical parameters affecting cell growth, viability and the concentration of HCPs in the supernatant. The featured speaker will discuss how temperature and osmolality ...
-
Comprehensive Gene Therapy Development Solutions to Further Boost Rare Disease Research
As several gene therapy approvals for rare disease treatment gain steam in 2023, a comprehensive set of gene therapy development solutions is released to pave richer avenues for rare disease research. This path-breaking move sees the integration of cutting-edge technology with state-of-art research facilities to amplify the possibilities of devising effective remedies for rare diseases. Rare ...
By Protheragen
-
CD Formulation Introduces Comprehensive Range of Microsphere and Microneedle Solutions for Pharma and Biotech Applications
CD Formulation, a leading provider of innovative pharmaceutical formulation services, has recently launched a comprehensive range of microsphere and microneedle solutions for pharmaceutical and biotech applications. The newly introduced solutions are focused on long-acting controlled-release microspheres and phase-transition microneedle patches, to meet the growing demand for novel ...
-
CD Formulation Newly Launches 100+ Raw Materials for Preparation of Microspheres and Microneedles
Microsphere formulation has been highlighted as a promising dosage form in clinical practice due to its ability to significantly improve patient convenience and compliance. As a trustworthy partner in the field of pharmaceutical formulation, CD Formulation has newly introduced a range of raw materials for the production of microspheres and microneedles, which are highly expected to advance ...
-
CD Genomics Introduces Complete Plasmid DNA Sequencing Service Accelerating Genetic Research
CD Genomics, a globally recognized leader in genomics services, has recently unveiled its Complete Plasmid DNA Sequencing service, empowering researchers with cutting-edge solutions for genetic exploration. This service aims to provide scientists in various fields, such as molecular biology, genetics, and gene engineering, with exceptional support, enabling them to gain comprehensive insights ...
By CD Genomics
-
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
Clinically validated lipid nanoparticle (LNP) delivery technology will further strengthen Bayer’s gene therapy portfolio High potency ionizable lipid technology and LNP carriers allow for efficient, targeted, and transient delivery of gene editing RNA components to the liver Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the ...
By Bayer AG
-
CD Bioparticles Launches mRNA Transfection Reagents for Research Applications
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, recently introduced a line of highly efficient mRNA Transfection Reagents with low toxicity for research applications, including the mRNA Transfection Reagent, Stem mRNA Transfection Reagent, and mRNA/gRNA Transfection Reagent. mRNA transfection is the process of introducing and expressing mRNA ...
-
Emerging Trends in the BioPharma Industry that you Need to Know
Emerging trends in the biopharma industry include new developments in cancer treatments, advances in gene therapy, and more data-driven decision-making. As a leader in the sector, it’s important to be aware of these developments to make informed decisions about your organization’s direction. In this blog post, we’ll explore some of the most significant emerging trends in ...
By Brio Group
-
Viral Vector Manufacturing
In recent years, applications of viral vectors have found an encouraging new beginning in gene therapy and in vaccine development. What can viral vectors be used for? Substantial improvements in viral vector manufacturing, delivery, and safety have placed viral vector-based therapy at the forefront of modern medicine. Viral vectors can be used for the treatment of various ...
By Nuvonis
-
ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT
Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances its preclinical programs for Stargardt disease and Retinitis Pigmentosa into IND-enabling activities and clinical stage development ViGeneron GmbH, a next-generation gene therapy company, today announced the presentation of preclinical data on its program VG801 in ...
-
ViGeneron Announces Closing of Series A Financing to Drive Development of Next Generation Gene Therapy Pipeline
ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. Funds will advance development of ViGeneron’s next-generation ...
-
Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros
Strong market uptake of Nubeqa and Kerendia Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention High-value late-stage development portfolio Positive study outcomes from cell & gene therapy pipeline would provide potential upside Shift of resources enhances commercialization and competitiveness Acquired arm’s ...
By Bayer AG
-
AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics. Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for full gene ...
By Bayer AG
-
Viralgen receives cGMP certification to produce rAAV commercial grade product at new facility in San Sebastian, Spain
Certification expands Viralgen's capacity threefold and positions the company as a world-leading CDMO New facility operates single-use bioreactors from 50 to 2,000 liters and manufactures research, clinical and commercial grade rAAV vectors using Pro10™, the leading cell line on the market Viralgen Vector Core (Viralgen), an independently operated subsidiary of Asklepios ...
By Bayer AG
-
CD Bioparticles Announces Magnetofection Reagents for Gene Expression
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, recently introduced a series of Magnetofection Reagents for gene expression. By utilizing the Lipofection and Magnetofection transfection techniques, these reagents are suitable for all types of nucleic acids, including plasmid DNA, linearized DNA, siRNA, oligonucleotides, double-stranded RNA, ...
-
Virica Biotech Announces Industry Veteran, Beth Thompson-Webb, as Chief Commercial Officer
Virica Biotech Inc. (“Virica”), a leading supplier and developer of viral enhancers for scaling of viral medicines, announced today that Beth Thompson-Webb will be joining the company as Chief Commercial Officer (CCO), effective January 9, 2023. Based out of Boston, MA, Ms. Thompson-Webb will be leading Virica’s commercial efforts to drive global sales and new business growth. ...
-
Suono Bio, Inc. Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has entered into an exclusive world-wide patent license with Massachusetts Institute of Technology (MIT), Brigham and Woman’s Hospital, and Massachusetts General Hospital. The associated patents broadly cover foundational elements for the rapid, targeted delivery of drugs, including ...
By Suono Bio
-
CRISPR Off-Target Analysis Now Available with CD Genomics’ Bioinformatics-Analysis Platform
The Bioinformatics-Analysis is a subdivision of CD Genomics, providing reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, database construction services, and other related data analysis services. The company is pleased to announce the launch of the CRISPR off-target analysis service to help researchers optimize the CRISPR ...
By CD Genomics
-
Combines mesenchymal stem-cell-based product, with Kurve’s intranasal drug delivery technology
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing product. The results ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you